Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Nivolumab or Nivolumab/Relatlimab Prior to Chemoradiation in Operable Stage II/III Esophageal/GEJ Cancer
NCT03044613Phase 1Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2017
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab and relatlimab in esophageal cancer and gastroesophageal junction cancer (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Treatment-Related Adverse Events at 100 days. Started Jul 2017; status: active, not recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03044613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03044613.